BN Business News
Add your company to Business Communicator →

Business · 22/03/2024

Prospective Grant of an Exclusive Patent License: Adoptive T Cell Therapy Products Produced Using a Pharmacological p38 Mitogen-Activated Protein Kinase (MAPK) Inhibitor

The National Cancer Institute is considering granting an Exclusive Patent License to Poolbeg Pharma (UK) Limited to practice inventions related to adoptive T cell therapy products.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights